These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 23361574)
1. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Jin YJ; Chung YH; Kim JA; Park W; Lee D; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Kim PN; Sung KB Dig Dis Sci; 2013 Jun; 58(6):1758-65. PubMed ID: 23361574 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy. Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193 [TBL] [Abstract][Full Text] [Related]
3. Lipiodol accumulation patterns and their impact on survival outcomes in transarterial chemoembolization for hepatocellular carcinoma: a single institution retrospective analysis. Bannangkoon K; Hongsakul K; Tubtawee T Sci Rep; 2024 Aug; 14(1):18979. PubMed ID: 39152197 [TBL] [Abstract][Full Text] [Related]
4. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. Lee JK; Chung YH; Song BC; Shin JW; Choi WB; Yang SH; Yoon HK; Sung KB; Lee YS; Suh DJ J Gastroenterol Hepatol; 2002 Jan; 17(1):52-8. PubMed ID: 11895553 [TBL] [Abstract][Full Text] [Related]
5. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428 [TBL] [Abstract][Full Text] [Related]
6. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma. Jeong SO; Kim EB; Jeong SW; Jang JY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ; Goo DE; Park SY Gut Liver; 2017 May; 11(3):409-416. PubMed ID: 28208001 [TBL] [Abstract][Full Text] [Related]
7. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160 [TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326 [TBL] [Abstract][Full Text] [Related]
9. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Kim DY; Ryu HJ; Choi JY; Park JY; Lee DY; Kim BK; Kim SU; Ahn SH; Chon CY; Han KH Aliment Pharmacol Ther; 2012 Jun; 35(11):1343-50. PubMed ID: 22486716 [TBL] [Abstract][Full Text] [Related]
10. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346 [TBL] [Abstract][Full Text] [Related]
11. No lipiodol, no beads-another transcatheter arterial chemoembolization (TACE) with fine cisplatin powder and porous gelatin particles for TACE-naïve, multifocal, up-to-seven out hepatocellular carcinoma. Sato R; Moriguchi M; Saiga A; Asahara K; Aramaki T Cancer Med; 2024 Jul; 13(14):e7446. PubMed ID: 39015047 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. Jun CH; Ki HS; Lee HK; Park KJ; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS World J Gastroenterol; 2013 Jan; 19(2):284-9. PubMed ID: 23345952 [TBL] [Abstract][Full Text] [Related]
14. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. Jin YJ; Lee JW; Choi YJ; Chung HJ; Kim YS; Lee KY; Ahn SI; Shin WY; Cho SG; Jeon YS J Gastrointest Surg; 2014 Mar; 18(3):555-61. PubMed ID: 24420729 [TBL] [Abstract][Full Text] [Related]
15. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. Rou WS; Lee BS; Moon HS; Lee ES; Kim SH; Lee HY World J Gastroenterol; 2014 Jun; 20(22):6995-7004. PubMed ID: 24944494 [TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761 [TBL] [Abstract][Full Text] [Related]